Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Justin M. Asquith"'
Publikováno v:
Translational Cancer Research. 5:S1149-S1152
Publikováno v:
Pediatric Transplantation. 19:E157-E159
For patients with DBA who are transfusion dependent, HSCT is the only cure. Chronic transfusions can lead to cirrhosis secondary to iron overload, making them poor candidates for myeloablative HSCT. RIC regimens are associated with lower morbidity an
Autor:
Daniel J. Hicklin, John G.M. Ullman, Elizabeth M. Jaffee, Elizabeth A. Manning, Justin M. Asquith, Todd D. Armstrong, Leisha A. Emens, Timothy R. Hansen, James M. Leatherman
Publikováno v:
Clinical Cancer Research. 13:3951-3959
Purpose: Given the complex tumor microenvironment, targeting multiple cellular components may be the most effective cancer treatment strategy. Therefore, we tested whether antiangiogenic and immune-based therapy might synergize by characterizing the
Autor:
Tianna Dauses, Vered Stearns, Jennifer N. Uram, Elizabeth Garrett-Mayer, Gang Chen, Saadet Atay-Rosenthal, Justin M. Asquith, Nancy E. Davidson, Elizabeth M. Jaffee, Maithili M. Daphtary, Leisha A. Emens, Elizabeth M. Duus, Maureen Berg, Richa Gupta, Kellie Hirt, John H. Fetting, James M. Leatherman, Silvia Petrik, Xiaobu Ye, Marina Laiko, Antonio C. Wolff
Granulocyte-macrophage colony-stimulating factor (GM-CSF)–secreting tumor vaccines are bioactive, but limited by disease burden and immune tolerance. Cyclophosphamide augments vaccine activity in tolerant neu mice and in patients with metastatic br
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74843e9b7ff25d1e0a040fe740a6b481
https://europepmc.org/articles/PMC4211036/
https://europepmc.org/articles/PMC4211036/
Autor:
Leisha A. Emens, Steven Piantadosi, Elizabeth M. Jaffee, Justin M. Asquith, Marina Laiko, Vered Stearns, Barbara A. Biedrzycki, Barry Kobrin, Silvia Petrik, John H. Fetting, Antonio C. Wolff, James M. Leatherman, Nancy E. Davidson, Mary L. Disis, Maithili M. Daphtary, Xiaobu Ye, Joy Levi
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 27, iss 35
Purpose Granulocyte-macrophage colony-stimulating factor (GM-CSF) –secreting tumor vaccines have demonstrated bioactivity but may be limited by disease burdens and immune tolerance. We tested the hypothesis that cyclophosphamide (CY) and doxorubici
Autor:
Elizabeth Garrett-Mayer, Justin M. Asquith, Elizabeth M. Jaffee, J. Levi, Vered Stearns, James M. Leatherman, Marina Laiko, R. Gupta, Nancy E. Davidson, Leisha A. Emens, Tianna Dauses, Antonio C. Wolff, Maithili M. Daphtary, Barry Kobrin, Silvia Petrik, S. Atay-Rosenthal, Xiaobu Ye
Publikováno v:
Journal of Clinical Oncology. 29:2535-2535
2535 Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccines are bioactive, but limited by disease burdens and immune tolerance. Cyclophosphamide (CY) augment...
Autor:
Justin M. Asquith, Maithili M. Daphtary, Nancy E. Davidson, Mary L. Disis, James M. Leatherman, S Piantadosi, Silvia Petrik, Leisha A. Emens, John H. Fetting, Elizabeth M. Jaffee
Publikováno v:
Journal of Clinical Oncology. 26:3009-3009
3009 Background: Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccines have shown promise, but their activity is limited by immune tolerance. We tested the hypothesis that integrating vaccination with cyclophosphamide (CY